Elisigen
June 23, 2026
Theater 3
Type: Company Presentation
Focus Area:
Cell and Gene Therapy and Genome Editing
Elisigen (formerly Neuracle Genetics) is a clinical-stage biotechnology company focused on developing innovative AAV gene therapies to address critical unmet needs in retinal and neurological diseases. Leveraging proprietary technologies, our product candidates are designed for optimal safety and efficacy, aiming to broaden access to transformative treatments for patients worldwide.
Our lead candidate, NG101, is a best-in-class AAV gene therapy for wet age-related macular degeneration (wAMD). NG101 received Fast Track designation from the FDA, and is currently in a Phase 1/2a clinical trial. NG101 completed patient enrollments and has demonstrated promising efficacy at the lowest dose without any safety concerns.
Elisigen is advancing a robust preclinical pipeline, including:
EG103: A first-in-class AAV gene therapy for dry age-related macular degeneration (dAMD).
EG201: A first-in-class AAV gene therapy for neuropathic pain and Alzheimer's disease.
Company HQ City:
Seoul
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2018
Lead Product in Development:
NG101, is a best-in-class AAV gene therapy for wet age-related macular degeneration (wAMD). In November 2024, NG101 received Fast Track designation from the FDA, underscoring its potential to meet a significant medical need. Currently in a Phase 1/2a clinical trial, NG101 completed patient enrollments and has demonstrated promising efficacy at the lowest dose without any safety concerns.
CEO
Jong Mook Kim, PhD
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
3
When you expect your next catalyst update?
October 2026
What is your next catalyst (value inflection) update?
NG101 ph1/2a data update
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}